SICHUAN KELUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.25 CNY | +2.87% |
|
+3.66% | +11.02% |
| Jul. 02 | Kelun-Biotech to Buy Equipment from Affiliate | MT |
| Jul. 02 | Kelun-Biotech to Buy Equipment from Sichuan Kelun Pharmaceutical's Unit | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 33,821 | 27,803 | 26,621 | 37,335 | 42,829 | 51,306 | - | - |
| Enterprise Value (EV) 1 | 42,133 | 36,599 | 33,785 | 42,634 | 45,047 | 53,056 | 52,099 | 52,752 |
| P/E ratio | 36.1 x | 33.5 x | 24.3 x | 23.1 x | 18.3 x | 17.5 x | 16.1 x | 14 x |
| Yield | 1.81% | 1.64% | 2.25% | 2.31% | 2.75% | 1.92% | 2.03% | 3.28% |
| Capitalization / Revenue | 1.92 x | 1.69 x | 1.54 x | 1.97 x | 2 x | 2.21 x | 2.04 x | 1.8 x |
| EV / Revenue | 2.39 x | 2.22 x | 1.96 x | 2.25 x | 2.1 x | 2.28 x | 2.07 x | 1.85 x |
| EV / EBITDA | 17.9 x | 16.9 x | 13.3 x | 12.7 x | 9.26 x | 11.1 x | 9.91 x | 8.86 x |
| EV / FCF | - | - | - | - | 12,621,250 x | - | - | - |
| FCF Yield | - | - | - | - | 0% | - | - | - |
| Price to Book | 2.56 x | 2.07 x | 1.95 x | 2.45 x | 2.23 x | 2.32 x | 2.12 x | 1.95 x |
| Nbr of stocks (in thousands) | 1,439,786 | 1,430,179 | 1,406,277 | 1,403,045 | 1,474,304 | 1,590,876 | - | - |
| Reference price 2 | 23.49 | 19.44 | 18.93 | 26.61 | 29.05 | 32.25 | 32.25 | 32.25 |
| Announcement Date | 2/27/20 | 4/14/21 | 1/7/22 | 4/13/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17,636 | 16,464 | 17,277 | 18,913 | 21,454 | 23,238 | 25,201 | 28,489 |
| EBITDA 1 | 2,352 | 2,171 | 2,533 | 3,363 | 4,865 | 4,794 | 5,259 | 5,956 |
| EBIT 1 | 1,277 | 1,010 | 1,320 | 2,199 | 3,654 | 3,954 | 4,532 | 5,337 |
| Operating Margin | 7.24% | 6.13% | 7.64% | 11.63% | 17.03% | 17.02% | 17.98% | 18.73% |
| Earnings before Tax (EBT) 1 | 1,256 | 955 | 1,178 | 2,071 | 3,580 | 3,836 | 4,251 | 5,004 |
| Net income 1 | 937.9 | 829.4 | 1,103 | 1,709 | 2,456 | 2,844 | 3,102 | 3,554 |
| Net margin | 5.32% | 5.04% | 6.38% | 9.03% | 11.45% | 12.24% | 12.31% | 12.48% |
| EPS 2 | 0.6500 | 0.5800 | 0.7800 | 1.150 | 1.590 | 1.839 | 2.000 | 2.302 |
| Free Cash Flow | - | - | - | - | 3,569 | - | - | - |
| FCF margin | - | - | - | - | 16.64% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | 73.37% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | 145.32% | - | - | - |
| Dividend per Share 2 | 0.4250 | 0.3188 | 0.4260 | 0.6160 | 0.8000 | 0.6200 | 0.6533 | 1.056 |
| Announcement Date | 2/27/20 | 4/14/21 | 1/7/22 | 4/13/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,591 | 4,482 | 4,643 | 4,734 | 5,054 | 5,602 | 5,132 | 5,009 | 5,711 | 6,219 | 5,801 | 5,859 | 5,685 | 6,471 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 388.9 | 335.2 | 763.3 | 756.5 | 345.5 | 1,123 | 754.5 | 719.9 | 1,057 | - | - | - | - | - | - |
| Operating Margin | 8.47% | 7.48% | 16.44% | 15.98% | 6.84% | 20.05% | 14.7% | 14.37% | 18.5% | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | - | - | - | - | - | - | - | - | 492.8 | 1,026 | 604.6 | 569.2 | 555.1 | - | - |
| Net margin | - | - | - | - | - | - | - | - | 8.63% | 16.5% | 10.42% | 9.72% | 9.77% | - | - |
| EPS 2 | 0.1800 | 0.2000 | 0.4000 | 0.3500 | 0.2000 | 0.5200 | 0.3900 | 0.3600 | 0.3200 | 0.6700 | 0.5492 | 0.4785 | 0.1989 | 0.4750 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | 0.8601 | - | - | - | 0.9000 |
| Announcement Date | 1/7/22 | 4/18/22 | 8/29/22 | 10/30/22 | 4/13/23 | 4/25/23 | 8/29/23 | 10/30/23 | 4/11/24 | 4/24/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 8,313 | 8,797 | 7,164 | 5,299 | 2,219 | 1,750 | 793 | 1,446 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.534 x | 4.052 x | 2.828 x | 1.575 x | 0.4561 x | 0.3651 x | 0.1507 x | 0.2428 x |
| Free Cash Flow | - | - | - | - | 3,569 | - | - | - |
| ROE (net income / shareholders' equity) | 7.21% | 6.25% | 8.07% | 11.7% | 14.1% | 13% | 13.3% | 14.2% |
| ROA (Net income/ Total Assets) | 3.08% | 2.61% | 3.45% | 5.2% | 10.3% | 7.2% | 7.75% | 9.3% |
| Assets 1 | 30,420 | 31,729 | 31,959 | 32,829 | 23,744 | 39,505 | 40,023 | 38,216 |
| Book Value Per Share 2 | 9.160 | 9.380 | 9.720 | 10.90 | 13.00 | 13.90 | 15.20 | 16.50 |
| Cash Flow per Share 2 | 1.540 | 1.540 | 2.000 | 2.200 | 3.560 | 2.470 | 2.740 | 3.240 |
| Capex 1 | 1,297 | 1,225 | 983 | 883 | 1,768 | 1,294 | 1,366 | 1,415 |
| Capex / Sales | 7.35% | 7.44% | 5.69% | 4.67% | 8.24% | 5.57% | 5.42% | 4.97% |
| Announcement Date | 2/27/20 | 4/14/21 | 1/7/22 | 4/13/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
32.25
CNY
Average target price
42.04
CNY
Spread / Average Target
+30.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.02% | 7.08B | |
| +62.66% | 854B | |
| +40.42% | 636B | |
| -4.37% | 361B | |
| +17.16% | 324B | |
| +9.87% | 301B | |
| +15.66% | 247B | |
| +17.90% | 228B | |
| +14.86% | 177B | |
| +0.45% | 164B |
- Stock Market
- Equities
- 002422 Stock
- Financials Sichuan Kelun Pharmaceutical Co., Ltd.
